Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918140 | 0.95 | HPGD (0.52) | HPGDSMN1; SMN2EPHX2POLBKMT2A | |
| Trifluoroacetic Acid SCHEMBL3911182 | 0.90 | RHOC (0.42) | — | |
| SCHEMBL3920133 | 0.84 | TSHR (0.46) | HPGDSMN1; SMN2KMT2AALDH1A1LMNA | |
| Trifluoroacetic Acid SCHEMBL3923215 | 0.81 | LRRK2 (0.44) | HPGDSMN1; SMN2KMT2AMEN1MAPT | |
| Trifluoroacetic Acid SCHEMBL3910499 | 0.80 | ALDH1A1 (0.51) | SMN1; SMN2KMT2AMEN1GAAALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3923252 | 0.77 | KCNA3 (0.46) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3925125 | 0.76 | KCNA3 (0.45) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3909784 | 0.75 | AR (0.47) | KMT2AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3921377 | 0.74 | KMO (0.44) | SMN1; SMN2KMT2ANPC1RAB9AMAPT | |
| SCHEMBL3913226 | 0.71 | SLC6A4 (0.51) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667988-B1 | COUMARINS AS INOS INHIBITORS | AVENTIS PHARMA INC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-7538233-B2 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20050054681-A1 | Coumarins as iNOS inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054681-A1 | Coumarins as iNOS inhibitors | NOS2, NOS1, NOS3 | HPGD 36/4885SMN1; SMN2 4820/4885EPHX2 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.